Supplier of science-based natural ingredients, Embria® Health Sciences, announced today that its flagship immune health ingredient, EpiCor, received a new GRAS (Generally Recognized As Safe) designation at the impressive inclusion rate of up to 3 grams per serving in all food categories. In 2006, EpiCor was the subject of a GRAS determination that allowed its use at a proposed maximum intake of up to 500 mg per day. EpiCor’s newest GRAS status was achieved after an intensive review of safety and toxicology data by an independent panel of highly qualified scientists with extensive regulatory, pharmacology and toxicological experience, including affiliations with the Food and Drug Administration (FDA), Environmental Protection Agency (EPA) and National Institute of Health (NIH).
Based on this GRAS determination, food and beverage manufacturing companies can safely and legally include EpiCor at a highly efficacious level in all food and beverage offerings, some of which include bars, breads, broths, dried cereals, flavored drinks, frozen yogurt, fruit juices, hard candy, milk drinks, mints, processed juices, snack dips, soups, sports beverages, spreads, tea beverages and tofu.
"Consumers are focused now more than ever on the importance of maintaining a healthy immune system," stated Embria Health Sciences president, Paul Faganel. “EpiCor’s GRAS determinations give functional food and beverage manufacturers the opportunity to meet consumer demand for safe and effective immune balancing products that can be conveniently incorporated into their daily diet.”
About Embria Health Sciences and EpiCor:
Embria Health Sciences, www.embriahealth.com, combines science and nature to bring high-quality, research-based natural ingredients to the global human nutrition market. Embria’s flagship ingredient, EpiCor®, is an all-natural product designed to modulate and balance the human immune system and is manufactured using a proprietary technology, which produces vital metabolites, vitamins, minerals, and antioxidants that deliver nutritional benefits and support increased bioavailability. Recent human clinical studies show EpiCor significantly decreases the incidence of some common symptoms associated with seasonal allergies, and decreases the incidence and duration of cold and flu symptoms. EpiCor has also been shown to possess anti-inflammatory activity, and activates crucial defense cells (Natural Killer, T-, and B-cells). For more information on immune health, visit www.BalancedImmuneHealth.com